Research Article
The Interaction of lncRNA-HEIH and lncRNA-HULC with HBXIP in Hepatitis B Patients
Table 2
Clinical features of patients.
| | Parameter | HBV + HCC | HBV-HCC | |
| | Gender | | | | | Female | 10 | 12 | >0.05 | | Male | 15 | 13 | | | HBsAg | | | | | Negative | 0 | 25 | <0.05 | | Positive | 25 | 0 | | | Age | 45.62 ± 11.28 | 44.71 ± 9.98 | >0.05 | | ALP (U/L) | 166.29 ± 36.12 | 150.49 ± 29.98 | >0.05 | | ALB (g/L) | 34.56 ± 10.18 | 33.33 ± 17.24 | >0.05 | | TBIL (μmol/L) | 42.49 ± 10.36 | 45.05 ± 6.21 | >0.05 | | DBIL (μmol/L) | 31.75 ± 4.98 | 30.23 ± 5.69 | >0.05 | | AFP (μg/L) | 125.78 ± 19.27 | 126.09 ± 22.08 | >0.05 | | ALT (U/L) | 90.57 ± 12.14 | 91.07 ± 25.07 | >0.05 | | AST (U/L) | 111.15 ± 9.72 | 126.77 ± 25.69 | >0.05 | | HBV-DNA (copies/mL) | (8.21 ± 0.69) × 104 | 0 | <0.05 |
|
|
HBsAg: hepatitis B surface antigen; ALP: alkaline phosphatase; ALB: albumin; TBIl: total bilirubin; DBIl: direct bilirubin; AFP: alpha-fetoprotein; ALT: alanine aminotransferase; AST: aspartate aminotransferase.
|
